Laboratoires Pierre Fabre Secures EU Approval for BRAFTOVI® in Combination Therapy for Colorectal Cancer
Laboratoires Pierre Fabre has recently celebrated a significant milestone with the European Commission's (EC) approval for its cancer therapy BRAFTOVI® (encorafenib). This groundbreaking treatment is now authorized for use in conjunction with cetuximab and FOLFOX (which includes fluorouracil, leucovorin, and oxaliplatin) for adult patients suffering from metastatic colorectal cancer (mCRC) harboring the BRAFV600E mutation.
The EC's decision is firmly rooted in the promising outcomes of the phase 3 BREAKWATER trial, which evaluated the efficacy and safety of this innovative treatment regimen against traditional chemotherapy approaches that utilize oxaliplatin, with or without the addition of bevacizumab. The results from the trial were remarkable, showing a statistically significant enhancement in both the objective response rate and progression-free survival compared to the standard chemotherapy treatment.
During the BREAKWATER trial, the BRAFTOVI® combination demonstrated an impressive improvement in progression-free survival (PFS), measuring a median duration of 12.8 months, compared to just 7.1 months for those receiving conventional chemotherapy. This translates to a 51% reduction in the risk of death, showcasing the potential of this therapy to extend life expectancy for patients.
Furthermore, the findings revealed that the treatment led to a 60.9% objective response rate in patients, substantially greater than the 40.0% observed in the chemotherapy group. Additionally, 65.7% of patients receiving the new regimen achieved a confirmed objective response, a significant increase over the 37.4% seen in those treated with traditional chemotherapy.
Eric Ducournau, the CEO of Laboratoires Pierre Fabre, expressed enthusiasm regarding the approval, highlighting that this marks an unprecedented advancement in treatment for patients with BRAFV600E-mutant colorectal cancer. Ducournau stated, "We are greatly pleased to increase the accessibility of encorafenib in combination with cetuximab and FOLFOX for the first-line treatment of adult patients with BRAFV600E-mutated metastatic colorectal cancer. The EC's decision today represents the approval of the first targeted therapy available in the EU for this patient population in the first-line setting, marking a significant milestone that addresses a substantial unmet clinical need for patients and healthcare providers, who have had limited treatment options until now."
This strategic breakthrough not only promises enhanced treatment avenues for patients with previously restricted options but also reaffirms Laboratoires Pierre Fabre's commitment to meeting unfulfilled medical needs through innovative pharmaceutical solutions. The future looks promising for patients facing the challenges of metastatic colorectal cancer, with BRAFTOVI® paving the way for a new era of targeted therapy that could save lives.
The EC's decision is firmly rooted in the promising outcomes of the phase 3 BREAKWATER trial, which evaluated the efficacy and safety of this innovative treatment regimen against traditional chemotherapy approaches that utilize oxaliplatin, with or without the addition of bevacizumab. The results from the trial were remarkable, showing a statistically significant enhancement in both the objective response rate and progression-free survival compared to the standard chemotherapy treatment.
During the BREAKWATER trial, the BRAFTOVI® combination demonstrated an impressive improvement in progression-free survival (PFS), measuring a median duration of 12.8 months, compared to just 7.1 months for those receiving conventional chemotherapy. This translates to a 51% reduction in the risk of death, showcasing the potential of this therapy to extend life expectancy for patients.
Furthermore, the findings revealed that the treatment led to a 60.9% objective response rate in patients, substantially greater than the 40.0% observed in the chemotherapy group. Additionally, 65.7% of patients receiving the new regimen achieved a confirmed objective response, a significant increase over the 37.4% seen in those treated with traditional chemotherapy.
Eric Ducournau, the CEO of Laboratoires Pierre Fabre, expressed enthusiasm regarding the approval, highlighting that this marks an unprecedented advancement in treatment for patients with BRAFV600E-mutant colorectal cancer. Ducournau stated, "We are greatly pleased to increase the accessibility of encorafenib in combination with cetuximab and FOLFOX for the first-line treatment of adult patients with BRAFV600E-mutated metastatic colorectal cancer. The EC's decision today represents the approval of the first targeted therapy available in the EU for this patient population in the first-line setting, marking a significant milestone that addresses a substantial unmet clinical need for patients and healthcare providers, who have had limited treatment options until now."
This strategic breakthrough not only promises enhanced treatment avenues for patients with previously restricted options but also reaffirms Laboratoires Pierre Fabre's commitment to meeting unfulfilled medical needs through innovative pharmaceutical solutions. The future looks promising for patients facing the challenges of metastatic colorectal cancer, with BRAFTOVI® paving the way for a new era of targeted therapy that could save lives.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.